A protein called complement factor H (CFH) that fights infections also strengthens bones by helping bone-building cells and slowing bone-removing cells, according to Gram Research analysis. In a 2026 study, mice lacking CFH had significantly weaker bones and slower fracture healing, while human patients with osteoporosis had substantially lower CFH levels than those with healthy bones, suggesting CFH could become a target for new bone-disease treatments.
Scientists discovered that a protein called complement factor H (CFH), which helps fight infections, also plays a crucial role in keeping bones strong. According to Gram Research analysis, when this protein is present in healthy amounts, it helps bone-building cells work better while slowing down bone-removing cells. In studies with mice lacking this protein, bones became weaker, fractures healed slowly, and bone loss accelerated. Human patients with osteoporosis had significantly lower CFH levels, while those with stronger bones had higher amounts. This finding could lead to new treatments that boost this natural protein to prevent bone disease.
Key Statistics
A 2026 research article in the Journal of Bone and Mineral Research found that mice genetically lacking complement factor H (CFH) displayed reduced trabecular and cortical bone mass, decreased bone formation, and diminished bone strength compared to normal mice.
According to the 2026 study, patients with osteoporosis had significantly reduced plasma CFH levels, while CFH levels in bone marrow plasma were negatively correlated with fracture risk in the patient population studied.
The research demonstrated that CFH-deficient mice exhibited delayed fracture healing and accelerated bone loss following ovariectomy or high-fat diet feeding, indicating CFH becomes especially important under bone-stress conditions.
In laboratory studies, CFH overexpression or supplementation enhanced osteoblast differentiation in human bone marrow skeletal stem cells, while CFH-deficient cells showed impaired bone-building cell development.
The Quick Take
- What they studied: Whether a protein called complement factor H (CFH) that helps the immune system also helps build and maintain strong bones
- Who participated: Laboratory studies with human bone marrow cells, mice genetically engineered to lack CFH, and human patients with and without osteoporosis
- Key finding: CFH acts like a bone-building helper: it encourages cells that make bone while discouraging cells that break bone down. People with osteoporosis had significantly lower CFH levels than those with healthy bones
- What it means for you: This research suggests CFH could become a target for new osteoporosis treatments, though human clinical trials are still needed before any new therapies become available
The Research Details
Researchers used multiple approaches to understand CFH’s role in bone health. First, they studied human bone marrow cells in laboratory dishes, adding or removing CFH to see how it affected bone-building cells. Next, they created mice that couldn’t make CFH and compared their bones to normal mice. They measured bone density, strength, and healing ability. Finally, they measured CFH levels in blood samples from human patients with osteoporosis and compared them to people with healthy bones.
The researchers also tested what happened to CFH-deficient mice under stress conditions like menopause (simulated by removing ovaries) and poor diet (high-fat feeding) to see if CFH becomes even more important when bones are under extra pressure.
This multi-layered approach—from cells in dishes to whole animals to human patients—helps confirm that CFH really does affect bone health in meaningful ways.
This research approach matters because it connects basic science (what happens in cells) to real-world health (what happens in people). By studying both mice and humans, researchers can be more confident that findings aren’t just laboratory curiosities but actually relevant to human bone disease. The stress tests (menopause and poor diet) show that CFH might be especially important when bones face extra challenges.
This study was published in the Journal of Bone and Mineral Research, a top-tier scientific journal focused on bone health. The researchers used established methods for measuring bone density and strength. They tested their findings in multiple ways (cells, animals, and humans), which strengthens confidence in the results. However, the human data shows correlation (CFH levels match bone strength) rather than proof that CFH directly causes stronger bones—that would require clinical trials where some people receive CFH treatment.
What the Results Show
When researchers removed CFH from mice, their bones became significantly weaker in two ways: the outer shell (cortical bone) and the inner spongy part (trabecular bone) both lost density. These mice also had slower bone healing after fractures and experienced accelerated bone loss when their ovaries were removed (simulating menopause) or when fed a high-fat diet.
In laboratory studies, cells lacking CFH struggled to become bone-building cells (osteoblasts) but too easily became bone-removing cells (osteoclasts). When researchers added extra CFH or gave CFH supplements, bone-building improved significantly.
In human patients, the pattern was clear: people with osteoporosis had much lower CFH levels in their blood and bone marrow compared to people with healthy bones. Higher CFH levels correlated with stronger bones and lower fracture risk.
The research revealed that CFH works through multiple mechanisms. It doesn’t just help bone-building cells—it also actively restrains bone-removing cells. Blood markers of bone formation (P1NP) were lower in CFH-deficient mice, while markers of bone breakdown (TRAPc and CTX-1) were elevated. This suggests CFH tips the balance toward bone building and away from bone loss.
While CFH has been extensively studied for its immune functions, this is among the first research showing its direct role in bone health. Previous research established that immune system imbalances can affect bones, but identifying CFH as a specific bone-regulating factor is novel. The findings align with growing evidence that immune proteins do double duty—fighting infections and maintaining tissue health.
This research has important limitations. The human data shows that CFH levels correlate with bone strength, but doesn’t prove CFH causes stronger bones—other factors could explain both. The mouse studies are powerful but don’t guarantee the same effects occur in humans. No human clinical trials have tested whether giving people CFH actually prevents or treats osteoporosis. The study doesn’t explain exactly how CFH works at the molecular level. Finally, the sample size for human patients wasn’t specified in the available information.
The Bottom Line
Based on this research, CFH is a promising target for future osteoporosis treatments (moderate confidence). Current recommendations remain unchanged: adequate calcium and vitamin D intake, weight-bearing exercise, and screening for osteoporosis risk. Do not attempt to self-supplement with CFH—it’s not currently available as a consumer product, and this research is preliminary.
This research is most relevant to people at risk for osteoporosis (postmenopausal women, older adults, those with family history), people with diagnosed osteoporosis, and researchers developing new bone-health treatments. It’s less immediately relevant to people with healthy bones, though understanding bone biology benefits everyone.
If CFH-based treatments are developed, they would need several years of human clinical trials before becoming available. Realistic timeline: 5-10 years before any CFH therapy might reach patients, assuming promising early trials.
Frequently Asked Questions
What is complement factor H and why does it matter for bones?
Complement factor H (CFH) is a protein known for fighting infections, but research shows it also helps build strong bones by encouraging bone-building cells and limiting bone-removing cells. People with osteoporosis have significantly lower CFH levels than those with healthy bones.
Can I take CFH supplements to prevent osteoporosis?
CFH supplements aren’t currently available for consumers. While this research is promising, human clinical trials haven’t been conducted yet. Stick with proven approaches: adequate calcium and vitamin D, weight-bearing exercise, and bone density screening if at risk.
How does this research change osteoporosis treatment?
This research identifies CFH as a potential new treatment target, but no CFH-based therapies exist yet. Current osteoporosis treatments remain the standard. If CFH treatments are developed, they would need years of human testing before becoming available to patients.
Does everyone need to worry about CFH levels?
People at high risk for osteoporosis—postmenopausal women, older adults, those with family history—should be most interested. Currently, CFH testing isn’t part of standard bone health screening, though that could change if treatments are developed.
What should I do now based on this research?
Continue proven bone-health practices: get adequate calcium (1000-1200 mg daily), vitamin D (600-800 IU daily), do weight-bearing exercise, and ask your doctor about bone density screening if you’re at risk. This research suggests future treatments, not immediate changes.
Want to Apply This Research?
- Track bone health markers: record any fractures, falls, or bone pain; monitor adherence to calcium/vitamin D intake and weight-bearing exercise; note any family history of osteoporosis or bone disease
- Set reminders for daily weight-bearing exercise (walking, dancing, light resistance training) and adequate calcium intake. Use the app to log these activities and correlate them with any bone health improvements over months
- Establish a baseline by recording current bone health status, then track exercise consistency and nutritional intake monthly. Schedule annual DEXA scans (bone density tests) if at risk, and log results in the app to visualize bone health trends over time
This article summarizes research findings and is for educational purposes only. It does not constitute medical advice. Complement factor H (CFH) is not currently available as a consumer supplement or treatment. Do not attempt to self-treat osteoporosis or bone disease based on this research. Consult your healthcare provider about bone health screening, prevention strategies, and treatment options appropriate for your individual circumstances. If you have osteoporosis or are at risk, work with your doctor to develop a personalized treatment plan using proven therapies.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.